Phase 3 N=30 Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections
Refractory Bone or Joint Infections
Primary: Clinical Success at 6 Months — 18; 9; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=44 Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections (OTTER)
Bone and Joint Infection
Primary: Quantify the Tolerability of Tedizolid for Bone and Joint Infections, Both Hardware and Non-hardware Associated — 0; 0 participants
N/A N=262 Acinetobacter Baumannii-related Osteomyelitis: Clinical and Epidemiological Characterization
Osteomyelitis
Primary: Description of the Clinical and Epidemiological Profile of Patients With Infection — 92; 26; 25; 21 Participants
Phase 2 N=29 Study to Assess Safety and Clinical Activity of Local MBN-101 in Treatment of Infected Bone Sites
Bacterial Infection
Primary: Number of Participants With Adverse Events — 5; 4; 1; 6 participants
Phase 4 N=1,054 Oral Versus Intravenous Antibiotics for Bone and Joint Infections (OVIVA B&J)
Bone Infection · Joint Infection
Primary: The Frequency of Definite Failure of Infection Treatment. — 67; 74 Participants
N/A N=260 MICRO Study: Detecting Bacterial Infections Related to Orthopaedic Surgical Implants
Open Reduction and Internal Fixation of Extremity Fractures
Primary: Number of Blood Samples With High Levels of Absorbance Via ELISA for Patients (Greater Than 1.5 Ratio Compared to Control Human Serum) — 48; 53 blood draw samples
N/A N=28 The Influence of Antibiotic Prophylaxis on Intraoperative Prosthetic Joint Infection Cultures
Prosthetic Joint Infection
Primary: Positive Cultures — 7; 7 cultures
N/A N=142 BBOT: Bacterial Burden in Ortho Trauma Procedures
Orthopaedic Trauma Infections
Primary: Number of Participants With Tissue Samples Identified With Bacterial DNA According to Highly Sensitive Bacterial Assays — 10; 24; 20 Participants
Phase 2 N=11 Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children
Hematogenously Acquired Staphylococcus Aureus Osteomyelitis · Bone Infection · Osteomyelitis
Primary: Incidence of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Deaths and Discontinuations Due to Adverse Events (AEs) — 1 incidence
N/A N=32 Microcurrent Dressing to Treat Infections, Before, During and After Surgery
Shoulder Arthropathy Associated With Other Conditions · Shoulder Arthritis · Shoulder Osteoarthritis
Primary: Measurement of Change in Cutibacterium Acnes — 3; 8; 3; 2 Participants — p=0.004
Phase 4 N=20 Acute Application of Antibiotic Powder in Open Fracture Wounds
Fractures, Open · Wounds and Injuries--Infections · Anti-Bacterial Agents
Primary: Incidence of Surgical Site Infection During the Post-operative Follow-up Period — 0; 0; 0 participants
N/A N=146 Antibiotic Prophylaxis in Orthopaedic Traumatology
Fractures, Closed · Wounds and Injuries
Primary: Number of Participants With Total Wound Infections — 4; 9 participants — p==0.12
N/A N=182 Less Infections for the Diabetic Foot
Diabetic Foot
Primary: Number of Participants Experiencing Clinical Failure — 26; 30 Participants
N/A N=30 Management of Traumatic Bone Defects in Tibial Plateau Fractures With Antibiotic-Impregnated Biodegradable Calcium Sulfate Beads: A Prospective Clinical Trial
Tibial Fractures · Intra-Articular Fractures · Fracture Fixation, Internal
Primary: Resorption of Study Device — 4 Participants
Phase 4 N=23 Intraosseous Vancomycin in Primary Total Hip Arthroplasty - Designing a Protocol
Prosthetic Joint Infection · Vancomycin · Joint Diseases
Primary: Systemic Vancomycin Level - Start of Case — 27.98; 0 ug/mL
Phase 4 N=87 Prophylaxis of Periprosthetic Joint Infections With Calcium Sulfate Beads in Patients With Non-modifiable Risk Factors.
Infection
Primary: Partipants Achieving a Lower Hip or Knee Periprosthetic Joint Infection Rate With Local Versus Conventional Intravenous Antibiotic Prophilaxys, Measured With CRP, ERS in…
Phase 4 N=60 Antibiotic Elution in Total Knee Arthroplasty
Total Knee Replacement
Primary: Amount of Vancomycin and Tobramycin Eluted From Hand Mixed Cement With Both Antibiotics After Total Knee Arthroplasty — 23.9; 30.6; 12.6; 16.2 mg/mL
Phase 4 N=160 Antibiotics Usage in Pediatric Orthopaedic Percutaneous Surgery (APOPS)
Supracondylar Humerus Fracture · Post Operative Wound Infection
Primary: Number of Participants With the Presence of Post-Operative Infection — 2; 2 Participants
Phase 2 N=75 Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci
Osteomyelitis
Primary: Any Creatine Phosphokinase (CPK) Elevation > 500 Units Per Liter (U/L) — 4; 5; 2 Participants
Phase 2 N=15 Safety and Efficacy in Patients Treated for Hip or Knee PJI With Vancomycin and Tobramycin Joint Irrigation
Prosthetic Joint Infection
Primary: Safety Evaluations: Number and Frequency of Adverse Events Among Participants — 14; 14; 14; 14 Participants
N/A N=91 Topical Antibiotic Treatment for Spine Surgical Site Infection
Surgical Wound Infection
Primary: Surgeon Attitudes About Using Intra-wound Antibiotics for Spine Surgery — 9; 36; 46 Participants
N/A N=225 Incidence and Risk Factors for Surgical Site Infection After Intramedullary Nailing of Femoral and Tibial Fractures
Fracture Fixation, Intramedullary · Surgical Wound Infection
Primary: Incidence of Surgical Site Infection (SSI) Relating to Intramedullary Nailing for Fixation of Diaphyseal Femoral and Tibial Fractures — 26; 195 Participants
Phase 3 N=42 Combination Antibiotic Treatment for Reactive Arthritis Caused by Chlamydia Bacteria
Arthritis, Reactive · Reiter Disease
Primary: Investigate Whether a 6 Month Course of Combined Antibiotics Was Effective Treatment. — 10; 7; 3 participants — p=0.01
N/A N=33 Use of a Reinforced Injectable Calcium Phosphate Bone Cement in the Treatment of Tibial Plateau Fractures
Tibial Fractures
Primary: Duration of Time the Patient Was in the OR as a Measure of Effectiveness of the Treatment — 107.0 Minutes
Phase 2 N=56 Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma
Metastatic Osteosarcoma · Recurrent Osteosarcoma · Refractory Osteosarcoma
Primary: Disease Control Rate (Cohort I) — 1 participants
N/A N=120 Bacterial Resistance in Patients Receiving Post-Intravitreal Injection Antibiotics
Bacterial Resistance
Primary: Number of Participants With Resistance of Ocular Flora to Commonly Used Post-injection Prophylactic Antibiotics — 10; 6 Participants
Phase 3 N=22 Regional Prophylactic Vancomycin in Revision Total Knee Replacement
Arthropathy of Knee Joint
Primary: Mean Concentration of Vancomycin in Subcutaneous Fat — 94.1; 3.2; 88.3; 5.0 µg/g — p=<0.0001
N/A N=2 ICG 24h Prior to Operative Treatment of Orthopaedic Infection
Trauma Injury · Bone Infection
Primary: Study Design Feasibility for Preoperative ICG Perfusion Rate as a Predictability Factor for Infection: Measured as Percentage of Patients With Analyzable Data — 0…
N/A N=156 Diagnostic Utility of a Novel Point-of-Care Test of Calprotectin for Revision Total Knee Arthroplasty
Prosthetic Joint Infection
Primary: Calprotectin POC — 1; 3; 52; 29 Participants
N/A N=117 Heterotopic Ossification Prophylaxis
Acetabular Fracture · Heterotopic Ossification
Primary: Number of Participants With Severe HO Formation — 3; 9 Participants